Mark Sabag Sells 216,892 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) insider Mark Sabag sold 216,892 shares of the business’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the completion of the sale, the insider directly owned 52,828 shares in the company, valued at approximately $1,517,748.44. This represents a 80.41% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Teva Pharmaceutical Industries Trading Up 1.2%

TEVA traded up $0.36 during midday trading on Thursday, hitting $30.16. 9,875,317 shares of the company were exchanged, compared to its average volume of 11,815,374. The firm’s 50 day moving average price is $23.03 and its 200-day moving average price is $19.44. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $30.20. The firm has a market capitalization of $34.59 billion, a P/E ratio of 50.27, a P/E/G ratio of 1.53 and a beta of 0.67. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. UBS Group lifted their price objective on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 8th. Bank of America lifted their target price on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday. JPMorgan Chase & Co. boosted their target price on shares of Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Finally, Barclays initiated coverage on Teva Pharmaceutical Industries in a report on Tuesday. They set an “overweight” rating and a $35.00 price target for the company. Three equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $30.25.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Advisors Asset Management Inc. acquired a new position in shares of Teva Pharmaceutical Industries during the second quarter worth approximately $41,000. Cromwell Holdings LLC raised its holdings in Teva Pharmaceutical Industries by 40.3% during the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock worth $44,000 after buying an additional 629 shares during the last quarter. Sound Income Strategies LLC raised its holdings in Teva Pharmaceutical Industries by 3,715.8% during the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock worth $49,000 after buying an additional 2,824 shares during the last quarter. MAI Capital Management lifted its stake in shares of Teva Pharmaceutical Industries by 26.8% in the second quarter. MAI Capital Management now owns 3,293 shares of the company’s stock valued at $55,000 after buying an additional 697 shares in the last quarter. Finally, Rothschild Investment LLC grew its holdings in shares of Teva Pharmaceutical Industries by 97.0% during the third quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock valued at $55,000 after buying an additional 1,348 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.